

UCLA

David Geffen School of Medicine

Dumont-UCLA Transplant Center, Dumont-UCLA Liver Cancer Center,
and Pflieger Liver Institute

Present

17th Annual UCLA Liver Diseases Symposium

Available as both LIVE in-person and virtual learning

2024



Saturday, October 26, 2024
8:30 am – 12:45 pm (PDT)

A Hybrid CME Conference

Hyatt Regency Westlake
880 S. Westlake Blvd
Westlake Village, CA 91361

17th Annual UCLA Liver Diseases Symposium

Program

- 7:15 **Registration & Breakfast**
- 8:25 **Welcome & Introduction**
Samer Ebaid, MD, PhD
- 8:30 **New Concepts in Portal Hypertension and Risk Stratification of Patients with Liver Cirrhosis**
Jasleen Singh, MD
- 8:55 **Changes in Evaluation, Listing and Organ Allocation in Liver Transplantation**
Fady Kaldas, MD
- 9:20 **Radiologic Treatment of Refractory Hepatic Encephalopathy, Ascites and Variceal Bleeding**
James Zhe Hui, MD, PhD
- 9:45 **Panel Case Discussion: Multi-disciplinary Approach to Liver Cancer**
Moderator: *Beshoy Yanny, MD*
Panel Presenters: *Vatche Agopian, MD*
Gina Choi, MD
Richard S. Finn, MD
James Zhe Hui, MD, PhD
- 10:15 **Break**

A Hybrid CME Conference

Saturday, October 26, 2024

Program

- 10:30 **New Therapies in Primary Biliary Cholangitis and Approaches in Autoimmune Hepatitis**
Sentia Iriana, MD, MS
- 10:55 **Current Evaluation and Treatment of Metabolic Dysfunction Associated Liver Disease**
Sammy Saab, MD, MPH
- 11:20 **Multidisciplinary Approach for Patients with Alcohol Related Liver Disease including those with Alcohol Hepatitis ~ Perspectives from Hepatology and Addiction Medicine**
Akshay Shetty, MD & Julio Meza, MD
- 11:50 **Evaluating Drug Induced Liver Injury ~ When to be Concerned**
Gina Choi, MD
- 12:15 **Panel Case Discussion: *Acute on Chronic and Fulminant Liver Failure***
Moderator: *Tien Dong, MD, PhD*
Panel Presenters: *Steven Han, MD*
Douglas Farmer, MD
- 12:45 **Adjourn**
Douglas Farmer, MD
- 1:00 **(Non-CME) Product Theater Begins**
- 2:00 **Product Theater Adjourns**

General Information

Saturday, October 26, 2024

8:30 am – 12:45 pm

Where:

Hyatt Regency Westlake
880 S. Westlake Blvd
Westlake Village, CA 91361
805-557-1234

Conference Location:

Barcelona/Cataluna Ballroom

Parking:

Self Parking – Complimentary
Valet Parking – \$15 per vehicle

Enrollment:

To register using a credit card or AHC/
electronic transfer, please visit: <https://ucla.cloud-cme.com/LD2024> and click register.

*Credit card and check payments via
phone, fax, or mail are no longer accepted.

**In-person attendees will be provided
breakfast and refreshments at the
conference.**

The 17th Annual UCLA Liver Diseases Symposium will also be available through a live virtual meeting web platform.

- Attendees who choose to attend the live virtual activity will receive a virtual meeting link and password to access the live virtual conference.
- All registrants (live or virtual) will be provided the opportunity to review recorded sessions up to 3 weeks following the conference.
- The recorded sessions are not certified for CME credit.

Any questions, please email the UCLA CCPD Office at ccpd@mednet.ucla.edu, or call 310-794-2620.

Accreditation

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The **California State Board of Registered Nursing** accepts courses approved for the *AMA PRA Category 1 Credits™* as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

The **American Board for Transplant Certification (ABTC)** has approved this educational offering for up to 4.25 Category One Continuing Education Points for Transplant Certification (CEPTCs).

Disclosure Statement

The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manages all identified potential conflicts of interest prior to the program. We, at UCLA, fully endorse the letter and spirit of these concepts.

17th Annual UCLA Liver Diseases Symposium

A Hybrid CME Conference

17th Annual UCLA Liver Diseases Symposium
A Hybrid CME Conference

C13403

Saturday, October 26, 2024

In-Person & Virtual Registration Fees

\$50 Physicians

\$35 Nurses and Other Allied Healthcare Professionals

\$25 Fellows and Residents



To register using a credit card or AHC/electronic transfer, please visit: <https://ucla.cloud-cme.com/LD2024> and click register.

*Credit card and check payments via phone, fax, or mail are no longer accepted.

Due to the low enrollment fee, no refunds will be offered. A full refund will be provided if this course is cancelled, or postponed.

Questions

If you have questions about enrollment, please call (310) 794-2620 or email: ccpd@mednet.ucla.edu.

Please visit our website for other conference offerings at <https://ucla.cloud-cme.com/default.aspx>

Course Description

The 17th Annual UCLA Liver Diseases Symposium will provide a state-of-the-art update and scientific exchange on prevalent liver diseases and their complications using a multi-disciplinary approach with hepatologists, radiologists, addiction medicine, and surgeons.

Target Audience

This conference will be targeted to hepatologists, radiologists, surgeons, gastroenterologist, oncologists, internists, family medicine clinicians, as well as allied health professionals.

Course Objectives

At the conclusion of this program, participants will be able to:

- Diagnose and manage patients with advanced liver disease and be better able to prognosticate and risk stratify those patients for medical procedures.
- Understand the current process of evaluation, listing and organ allocation in liver transplantation.
- Identify the risks and benefits of interventional radiology (IR) procedures for the management and treatment of clinically significant portal hypertension in patients with advanced liver disease.
- Use evidence-based recommendations in the evaluation and management of hepatocellular carcinoma (HCC).
- Discuss the role of current and recently approved second line therapies in the treatment of primary biliary cholangitis (PBC).
- Evaluate and properly stratify patients with metabolic dysfunction-associated steatotic liver disease (ie, fatty liver), and develop tailored therapies to prevent disease progression.
- Review treatment options for patients with alcohol hepatitis and optimal long-term care.
- Identify the most common causes of drug induced liver injury (DILI) and learn to assess which cases are likely to resolve or progress.
- Diagnose acute liver failure, risk stratify patients, and identify those likely to recover and those likely to require a liver transplant.

Course Faculty

CHAIR

Sammy Saab, MD, MPH, AGAF, FACG, FAASLD

Professor of Medicine and Surgery*
Medical Director, Pflieger Liver Institute
Medical Director, Adult Liver Transplant Program
Chief, Transplant Hepatology
Head, Outcomes Research in Hepatology
Adjunct Professor of Nursing

CO-CHAIR

Fady Kaldas, MD, FACS

Professor of Surgery*
Kelly Lee Tarantello Chair in Liver Transplantation
Director, Multi-Organ Transplantation Fellowship Program
Director, Liver Transplant Service
Co-Director, Heart – Liver Disease Program

FACULTY

Vatche G. Agopian, MD

Professor of Surgery*
Director, Liver Cancer Center
Associate Director, General Surgery Residency

Gina Choi, MD

Associate Professor of Medicine and Surgery*
Associate Director, Transplant Hepatology Fellowship Program

Tien Dong, MD, PhD

Assistant Clinical Professor of Medicine*

Samer Ebaid, MD, PhD, MS

Assistant Professor of Surgery*
Pflieger Liver Institute

Douglas G. Farmer, MD, FACS

Professor of Surgery*
Director, Intestinal Transplant Program
Director, Pediatric Liver Transplant Program
Interim Chief, Division of Liver and Pancreas Transplantation

Richard S. Finn, MD

Professor of Medicine*
Division of Hematology & Oncology

Steven-Huy B. Han, MD, AGAF, FAASLD

Professor of Medicine and Surgery*
Philip L. Palumbo Chair in Clinical Hepatology
Director, Transplant Hepatology Fellowship Program

James Zhe Hui, MD, PhD

Assistant Clinical Professor of Radiology

Sentia Iriana, MD, MS

Clinical Instructor of Medicine*

Julio Meza, MD

Assistant Clinical Professor*
Addiction Medicine
Family Health Center

Akshay Shetty, MD

Assistant Professor of Medicine and Surgery*

Jasleen Singh, MD

Clinical Instructor of Medicine and Surgery*

Beshoy T. Yanny, MD

Program Leader, Hepatology, UCLA Medical Center, Santa Monica
Assistant Clinical Professor of Medicine*
Vatche and Tamar Manoukian Division of Digestive Diseases

Center for Continuing Professional Development
UCLA David Geffen School of Medicine
BOX 956938, 885 Tiverton Drive, Suite 300
Los Angeles, CA 90095-6938

NON-PROFIT ORG.
U.S. POSTAGE
PAID
UNIVERSITY OF CALIFORNIA,
LOS ANGELES

17th Annual UCLA Liver Diseases Symposium

*Available as both LIVE in-person
and virtual learning*

**Saturday, October 26, 2024
8:30 am – 12:45 pm (PDT)**

A Hybrid CME Conference
**Hyatt Regency Westlake
880 S. Westlake Blvd
Westlake Village, CA 91361**